AXS-05 (dextromethorphan-bupropion)
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation in Patients With Dementia of the Alzheimer's Type
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Trial Timeline
Nov 21, 2024 → Apr 25, 2025
NCT ID
NCT06736509About AXS-05 (dextromethorphan-bupropion)
AXS-05 (dextromethorphan-bupropion) is a phase 3 stage product being developed by Axsome Therapeutics for Agitation in Patients With Dementia of the Alzheimer's Type. The current trial status is terminated. This product is registered under clinical trial identifier NCT06736509. Target conditions include Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06736509 | Phase 3 | Terminated |
| NCT04634669 | Phase 2 | Terminated |
Competing Products
20 competing products in Agitation in Patients With Dementia of the Alzheimer's Type